Skip to content

News

Asarina Pharma AB (publ) ("Asarina" or the "Company") announced on 13 September 2024 that the Company has applied for the delisting...
Stockholm, September 13, 2024. An extraordinary general meeting of Asarina Pharma AB (publ) ("Asarina" or the "Company") decided on...
Asarina Pharma AB (publ) held on 21 August 2024 an extraordinary general meeting, and first control meeting, at which the shareholders resolved that the...
The shareholders of Asarina Pharma AB (publ), reg. no. 556698-0750, (the “Company”) are hereby given notice to attend the extraordinary general...
Asarina Pharma AB (publ) ("Asarina Pharma” or the ”Company”) today announces that the Company is discontinuing its efforts to find...
The following resolutions were passed at the Annual General Meeting (the “AGM”) of Asarina Pharma AB (publ) (the “Company”) on...
(Stockholm, 4 June 2024) Asarina Pharma (“the Company”) today announces the release of its 2023 Annual Report. Status and OutlookSince completing...
Asarina Pharma AB (publ) (”the Company”) announces today that the Board has decided to postpone the release of the Annual Report for 2023 to...
Asarina Pharma AB (publ) (”the Company”) announces today that the Board has decided to postpone the release of the Annual Report for 2023 to...
(Stockholm, 27 February 2024) Asarina Pharma (“the Company”) today releases its Second Half-Year and Year-End Report for 2023. The full Report...